Navigation Links
Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
Date:12/8/2011

NEW HAVEN, Conn., Dec. 8, 2011 /PRNewswire/ -- Cenestra Health announces that the U.S. Patent and Trademark Office (the "USPTO") has issued a new U.S. patent, No. 8,071,646 (the "'646 patent"), that protects and provides Cenestra with exclusivity for highly pure formulations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in ratios ranging from about 3.5:1 to about 5:1.  The '646 patent provides exclusivity for these EPA:DHA ratios in compositions with > 84% omega-3s as the active ingredient. The '646 patent also provides exclusive rights to a number of uses for these superior EPA:DHA ratios.

While Cenestra's previously awarded U.S. patent No. 7,652,068 secured Cenestra's intellectual property on a composition of highly pure ethyl ester forms omega-3 formulations in EPA:DHA ratios of 4.1:1, the '646 patent greatly broadens the opportunity to develop highly unique and best in class EPA:DHA prescription products.  Both patents place Cenestra in a unique position to have therapeutically superior, patent protected products for treatment of diseases such as cardiovascular disease and depression.

"We are pleased that the USPTO recognized the novelty of these specific ratios of EPA to DHA that Cenestra discovered.  Cenestra's research shows that there are clearly superior ratios and dosages of these bioactive lipids for specified applications.  We hope to bring Cenestra's innovative products to patients afflicted with the illnesses that these specific ratios of omega-3s are optimized to treat," said Louis Sanfilippo, M.D., Assistant Clinical Professor at Yale School of Medicine and Managing Director of Cenestra Health.

"We believe that with the granting of the '646 patent, Cenestra finds itself in the unique position as the only high purity omega-3 company with straight-forward composition patents with long patent life remaining.  We believe this will allow Cenestra the ability to garner considerable investment in product development, and sales and marketing.  From the data Cenestra has generated to date, we expect the products developed under the Cenestra patents will confer superior efficacy to those currently on the market or announced to be in development," stated Dr. Sanfilippo. 

About Cenestra, LLC (D/B/A Cenestra Health)

Cenestra Health is a privately-held and unleveraged biopharmaceutical company based in New Haven, Connecticut. Cenestra Health was founded in 2005 to formulate, develop and market "best-in-class" proprietary natural products with applications in the OTC, medical food and pharmaceutical markets. Cenestra Health is focused on the clinical development of its late stage clinical drug candidates for the treatment of dyslipidemias and central nervous system disorders. Cenestra Health is planning to initiate Phase 3 registrational trials in early 2012.

About Omega-3 Essential Fatty Acids

Omega-3 fatty acids are considered "essential" fatty acids (EFAs) as they are necessary to human health but cannot be produced by the body. The two major health promoting omega-3 polyunsaturated fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA have been shown to promote good physical and emotional health, reduce the risk of cardiovascular disease, and exert powerful anti-inflammatory effects. Omega-3 prescriptions in the United States alone accounted for over $1 billion dollars in sales in 2010.

Statements made in this press release should not to be construed as making any specific claim or claims in the diagnosis, prevention or treatment of any disease or disorder but  may relate to historical facts and information that reflect forward looking statements based on Cenestra Health's intellectual property and scientific data.    

  
Investor Contact:  Louis Sanfilippo, M.D., Managing Director
Email: investor.relations@cenestrahealth.com
Telephone: 203-362-8919
Website: www.cenestrahealth.com

US Patent No. 7,652,068/Omega-3 Fatty Acid Formulations
US Patent No. 8,071,646/Omega-3 Fatty Acid Formulations


'/>"/>
SOURCE Cenestra Health
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery
4. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
5. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
6. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
7. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
8. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
9. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
10. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
11. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... of the QB3@953 life sciences incubator to ... health. The shared laboratory space at QB3@953 was created ... a key obstacle for many early stage organizations - ... of the sponsorship, Amgen launched two "Amgen Golden Ticket" ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):